Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Rutty

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Canadian Bulletin of Medical History = Bulletin Canadien D'Histoire De La Medecine|January 1, 1996
The middle-class plague: epidemic polio and the Canadian state, 1936-37C J Rutty
Chemico-Biological Interactions|February 1, 1980
In vitro cytotoxicity of the methylmelaminesC J Rutty, G Abel
Cancer Chemotherapy and Pharmacology|January 1, 1987
Metabolism of hexamethylmelamine in miceI R Judson, C J Rutty
Biochemical Pharmacology|December 15, 1977
In vitro studies with hexamethylmelamineC J Rutty, T A Connors
British Journal of Cancer|May 1, 1986
Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicityI R Judson, C J Rutty, G Abel, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1982
The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouseC J Rutty, D R Newell, J R Muindi, et al.
European Journal of Cancer|June 1, 1978
In vivo studies with hexamethylmelamineC J Rutty, T A Connors, Nguyen-Hoang-Nam, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activationC J Rutty, I R Judson, G Abel, et al.
Journal of Medicinal Chemistry|December 24, 1993
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methylM Jarman, H M Coley, I R Judson, et al.
Cancer Research|October 1, 1989
Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine)I R Judson, A H Calvert, C J Rutty, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Canadian Bulletin of Medical History = Bulletin Canadien D'Histoire De La Medecine|January 1, 1996
The middle-class plague: epidemic polio and the Canadian state, 1936-37C J Rutty
Chemico-Biological Interactions|February 1, 1980
In vitro cytotoxicity of the methylmelaminesC J Rutty, G Abel
Cancer Chemotherapy and Pharmacology|January 1, 1987
Metabolism of hexamethylmelamine in miceI R Judson, C J Rutty
Biochemical Pharmacology|December 15, 1977
In vitro studies with hexamethylmelamineC J Rutty, T A Connors
British Journal of Cancer|May 1, 1986
Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicityI R Judson, C J Rutty, G Abel, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1982
The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouseC J Rutty, D R Newell, J R Muindi, et al.
European Journal of Cancer|June 1, 1978
In vivo studies with hexamethylmelamineC J Rutty, T A Connors, Nguyen-Hoang-Nam, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activationC J Rutty, I R Judson, G Abel, et al.
Journal of Medicinal Chemistry|December 24, 1993
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methylM Jarman, H M Coley, I R Judson, et al.
Cancer Research|October 1, 1989
Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine)I R Judson, A H Calvert, C J Rutty, et al.
Pageof 1